GRAIL INC (GRAL)
Health Care · diagnostic equipment & services · NASDAQ
GRAIL is a pioneer in multi-cancer early detection, developing blood-based tests designed to identify multiple types of cancer at earlier, more treatable stages.
What GRAIL INC does
GRAIL, Inc. is a healthcare company focused on the early detection of cancer through multi-cancer early detection (MCED) blood testing. Its proprietary technology platform uses high-intensity sequencing and machine learning to identify circulating tumor DNA (ctDNA) patterns associated with multiple cancer types.
Themes: early cancer detection, liquid biopsy, precision oncology, genomics
Fundamentals
- Price$132.61 as of 2026-10-08 close
- Market cap$5.9B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+82.2% 2025-10-08 close $72.79 → 2026-10-08 close $132.61
- P/En/a negative earnings
- Net margin-277.5% FY2025, SEC XBRL
- ROE-15.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+23.1% as of 2026-09-03
- Revenue CAGR (3y)+25.7% SEC XBRL
- Beta2.57 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How GRAL compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GRAL is not currently in any published Top 10 list. Its scores are below.
Top 10 score
50.8 #684 of 1,379 scored · #86 of 151 in Health Care
Growth 84th (3-year revenue CAGR 25.7%, revenue growth year over year 23.1%) and trend 76th (a strong uptrend, with buyers in control); weakest is profitability (5th, operating margin -382%, return on equity -15.8%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How GRAIL INC looks technically
GRAIL INC (GRAL) is trading 76.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 19 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 20.3% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 76.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +76.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $90.72 | $90.72 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $75.14 | $75.14 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 73.46. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 19 trading days ago — a "golden cross", a bullish long-term signal | 19 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 76.5% above | +76.5% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with buyers in control | 56.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.9 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($92.00 to $166.47) — its "stochastic" reading is 55 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 54.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $166.47 | $166.47 |
|---|---|---|
| From the 52-week high | it is 20.3% below its 52-week high (its highest price of the past year) | -20.3% |
| Above the 52-week low | it is 219.5% above its 52-week low (its lowest price of the past year) | +219.5% |
| Below the 52-week high | it is 20.3% below its highest point of the past year | 20.3% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $166.47 (set on 2026-10-06) | $166.47 |
| Given back of the 52-week move | over the past year its closes ranged ($43.03 to $154.08), and it has given back roughly a quarter of its rise from last year’s low — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $81.90 to $85.45. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.3% |
| From the all-time high | it is 20.3% below its all-time high | -20.3% |
| Nearest price level | it is trading 17.8% above a support level at $108.99 — a price it turned at twice since 2026-01-12, most recently on 2026-02-18. Since 2024-10-08 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -17.8% |
| All-time low | its lowest closing price on record is $12.33 (set on 2024-10-07) | $12.33 |
| Above the all-time low | it is 975.5% above its all-time low | +975.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $10.21 between its high and its low — about 7.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $10.21 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $61.00 and $167.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $61.00 – $114.13 – $167.26 |
| Typical daily range (% of price) | its price moves about 7.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.7% |
| Stretch from the 200-day average | it is trading 5.6 daily ranges above its 200-day average price (76.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.05× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 13.4% since the prior reading | +13.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.2% |
|---|---|---|
| Open gap | it gapped 16.1% above the previous close 13 sessions ago and has not traded back through the level it left behind at 80.77 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +16.1% |
| Gap filled | a 2.2% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -13.93% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 66.6 percentage points (the stock gained 67.6% while the market gained 1.0%) | +66.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 85.2 percentage points (the stock gained 89.1% while the market gained 3.8%) | +85.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 138.8 percentage points (the stock gained 156.3% while the market gained 17.5%) | +138.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 67.2 percentage points (the stock gained 82.2% while the market gained 15.0%) | +67.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 74% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.7% of the share price. | +73.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 78% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $74.51 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +78.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 34% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $98.86 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | +34.1% |
Price levels it has turned at before
GRAL last closed at $132.61 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $108.99 | Support | 17.8% below the last close | turned there twice · 2026-01-12 to 2026-02-18 |
| $95.17 | Support | 28.2% below the last close | turned there twice · 2025-10-31 to 2025-12-22 |
| $84.68 | Support | 36.1% below the last close | turned there three times · 2025-12-17 to 2026-08-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $73.46.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $98.19 and $113.47 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $73.46.
This reading has stood for 14 trading days, since 2026-09-21.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.09 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$116.10 range $60.00 – $175.00; median $110.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GRAL
- Consensus EPS estimate-$1.90 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.5509 from -$2.45, on 2026-09-04, 35-day window
- Readings revised upward67% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant ongoing operating losses and potential need for additional capital","Regulatory risks related to FDA approval and clinical study outcomes","Intense competition in the diagnostics and screening market"]
What changed in the latest 10-Q
AI-assisted comparison of GRAL's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: 'unless otherwise indicated' reference paragraph moved earlier; previously this paragraph in newer filing omits the older disclosure about GRAIL being acquired by Illumina in August 2021 and the June 24, 2024 Spin-Off details.
- Newer filing adds: 'over 925,000 tests processed' (older: 'over 860,000 tests processed').
- Newer filing adds: 'international distributors' to list of partnerships (older list omitted international distributors).
- Newer filing adds: statement that results were presented at the Annual American Society of Clinical Oncology (ASCO) meeting in June 2026.
- Newer filing adds: PMA 'has been accepted by the FDA for review' (older stated only that the last module was submitted in January 2026).
- Newer filing adds: 'Galleri detected 366 Stage I and II cancers, more than the 290 cancers detected at any stage by the entirety of the U.K.'s standard of care screening program in the control arm.'
- Newer filing adds: 'Additionally, adding Galleri was associated with a 25% reduction in cancers diagnosed after emergency presentation. Emergency presentations are among the costliest cancer diagnoses and are associated with the poorest patient outcomes.'
- Newer filing adds: commercial Galleri test sales figures 'over 595,000 ... through June 30, 2026, with over 117,000 sold during the six months ended June 30, 2026' (older reported over 530,000 through March 31, 2026, with over 56,000 sold during the three months ended March 31, 2026).
- Newer filing adds: net loss figures for the three and six months ended June 30, 2026 and June 30, 2025 ($110.2 million and $114.0 million; $203.4 million and $220.2 million respectively), replacing older three-month figures for March 31, 2026 and March 31, 2025.
- Newer filing adds: Adjusted EBITDA figures for the three and six months ended June 30, 2026 and June 30, 2025 ($(90.3) million and $(78.3) million; $(170.2) million and $(177.1) million respectively), replacing older three-month figures for March 31, 2026 and March 31, 2025.
- Newer filing adds: new section heading 'Strategic Collaboration with Samsung and Closing of $110 million Equity Investment' and the beginning of text regarding issuance and sale of 1,570,308 shares of common stock to Samsung C&T Corporation in June.
- Removed:
- Older filing contained a paragraph about GRAIL's prior acquisition by Illumina in August 2021, the binding hold separate commitments, and the June 24, 2024 Spin-Off distribution of GRAIL common stock, including the ticker symbol 'GRAL'; this paragraph is absent in the newer filing.
- Older filing contained a sentence repeating the list of aggressive cancers detected after the commercial test sales figures; this sentence is absent in the newer filing.
- Older filing included the full name 'American Academy of Family Physicians ("AAFP")' with abbreviation in the list of medical conferences; newer filing omits the abbreviation 'AAFP'.
- Reworded:
- Newer filing changes 'our multi-cancer early detection test (“Galleri”)' to 'our multi-cancer early detection (“MCED”) test (“Galleri”)', adding the MCED abbreviation.
- Newer filing changes 'Recently we announced results' to 'Recently we presented results'.
- Newer filing changes 'our three year, randomized controlled NHS-Galleri Trial' to 'our three-year, randomized controlled NHS-Galleri Trial' (hyphenation).
- Newer filing changes 'although the primary endpoint of statistically significant combined stage 3 and 4 reduction was not observed' to 'Although the primary endpoint of statistically significant combined stage 3 and 4 reduction in a pre-specified group of 12 deadly cancers was not observed', with semicolon and wording adjustments regarding the favorable trend.
- Newer filing changes 'pre-market approval application (“PMA”)' to 'premarket approval application (“PMA”)' (removing hyphen in 'premarket').
- Newer filing changes 'payors, and life insurance providers' to 'payors, international distributors and life insurance providers'.
- Newer filing changes 'push down accounting' to 'pushdown accounting'.
- Newer filing changes 'intangible asset impairments' to 'intangible and other asset impairments'.
- Newer filing changed the net loss paragraph from reporting March 31, 2026 and March 31, 2025 three-month periods to June 30, 2026 and June 30, 2025 three-month and six-month periods.
- Newer filing changed the Adjusted EBITDA paragraph from reporting March 31, 2026 and March 31, 2025 three-month periods to June 30, 2026 and June 30, 2025 three-month and six-month periods.
- Notes:
- The newer filing excerpt ends mid-sentence in the new Samsung section ('...common stock to Samsung C&T Corporation (“'), so changes after that point, if any, could not be assessed.
- The older filing excerpt also appears truncated/divided by page number ('18') within the NHS-Galleri paragraph, but the surrounding text was readable.
- Both filings contain an apparent typographical issue 'parti cipant' (with a space) that persists in both versions and is not reported as a change.
Risk Factors
- Added:
- In the newer filing (filed 2026-08-06), a new risk factor paragraph titled 'We could be subject to additional securities class action litigation.' was added. It states that in February 2026, the company announced the NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction and experienced a decline in its stock price on the following day.
- In the newer filing (filed 2026-08-06), added detail about securities class action complaints filed on November 11, 2023 against Illumina and certain of its current and former executive officers alleging false and misleading statements relating to Illumina's acquisition of GRAIL.
- In the newer filing (filed 2026-08-06), added that in June 2026, a putative securities class action captioned Robbins v. GRAIL, Inc. et al. was filed against the Company and certain executive officers, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 regarding false and misleading statements about the NHS-Galleri trial.
- In the newer filing (filed 2026-08-06), added that in June 2026, a shareholder derivative action captioned Augitto v. Ragusa et al. was filed against the Company's current Board members and certain officers, alleging breach of fiduciary duties related to alleged false and misleading statements about the NHS-Galleri trial.
- In the newer filing (filed 2026-08-06), added a paragraph about shareholder activism risk, noting that any perceived or actual decline in business prospects or stock price following the NHS-Galleri Trial results or other adverse developments could invite shareholder activism.
- In the newer filing (filed 2026-08-06), exhibit list included exhibit 10.1 'Amended Offer Letter by and between the Company and Joshua Ofman' incorporated by reference from Form 8-K dated 6/1/26.
- In the newer filing (filed 2026-08-06), exhibit list included exhibit 10.2 'Amendment dated May 22, 2026, to Lease, dated September 11, 2025, by and between GRAIL, Inc. and Sunnyvale Office Acquisition, LLC.' filed herewith.
- In the newer filing (filed 2026-08-06), the signature page shows Joshua Ofman as Chief Executive Officer and Principal Executive Officer.
- Removed:
- In the older filing (filed 2026-05-07), the statement 'During the first quarter of fiscal year 2026, there were no material changes to our previously disclosed risk factors.' appeared in the Risk Factors section and is not present in the newer filing.
- In the older filing (filed 2026-05-07), exhibit list included exhibit 10.1 'Transition, Separation and Release Agreement, between GRAIL, Inc. and Robert Ragusa, dated March 11, 2026' incorporated by reference from Form 10-K dated 3/12/26, exhibit 10.15.
- In the older filing (filed 2026-05-07), the signature page shows Robert Ragusa as Chief Executive Officer and Principal Executive Officer.
- Reworded:
- The newer filing (filed 2026-08-06) switched the Chief Executive Officer signatory from Robert Ragusa (older filing, filed 2026-05-07) to Joshua Ofman (newer filing).
- Notes:
- This comparison covers only the provided text sections, which include the Risk Factors section and adjacent exhibit/signature portions from each filing.
- Some exhibit numbers (e.g., 10.2 in the newer filing, 10.1 in the older filing) were compared based on the exhibit table text provided.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 15 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 13 sells ($11M) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 15 sells ($12M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 16 sells ($12M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GRAL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GRAL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,661,515
- Reported value $454,781,739
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GRAL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GRAL had 8,565,314 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
GRAL had 19.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.66 days to cover at the same settlement.
- Reported short interest (shares) 8,565,314
- Short interest (% of shares outstanding) 19.2%
- Prior settlement (shares) 8,512,679
- Reported change 0.62%
- Days to cover (reported) 12.66
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Natera (NTRA)
- Invitae (NVTA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GRAL vs…
GRAIL INC is found in…
GRAL ranks in…
Frequently asked questions
What does GRAIL INC (GRAL) do?
GRAIL, Inc. is a healthcare company focused on the early detection of cancer through multi-cancer early detection (MCED) blood testing. Its proprietary technology platform uses high-intensity sequencing and machine learning to identify circulating tumor DNA (ctDNA) patterns associated with multiple cancer types.
What sector is GRAIL INC (GRAL) in?
GRAIL INC (GRAL) is classified in the Health Care sector. Its industry is diagnostic equipment & services. It trades on NASDAQ.
Who are GRAIL INC's (GRAL) competitors?
Notable peers of GRAIL INC (GRAL) include Exact Sciences, Guardant Health, Natera and Invitae. This peer set is informational only — not financial advice.
Is GRAIL INC (GRAL) overbought or oversold right now?
GRAIL INC (GRAL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GRAL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.